#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Brain substrates of early (4 h) cigarette abstinence: Identification of treatment targets Introduction Research indicates that overnight nicotine abstinence disrupts neural activity in the mesocorticolimbic reward network; however, less is known about the time course of abstinence-induced brain changes.
1-1	0-5	Brain	_
1-2	6-16	substrates	_
1-3	17-19	of	_
1-4	20-25	early	_
1-5	26-27	(	_
1-6	28-29	4	_
1-7	30-31	h	_
1-8	32-33	)	_
1-9	34-43	cigarette	_
1-10	44-54	abstinence	_
1-11	55-56	:	_
1-12	57-71	Identification	_
1-13	72-74	of	_
1-14	75-84	treatment	_
1-15	85-92	targets	_
1-16	93-105	Introduction	_
1-17	106-114	Research	_
1-18	115-124	indicates	_
1-19	125-129	that	_
1-20	130-139	overnight	_
1-21	140-148	nicotine	_
1-22	149-159	abstinence	_
1-23	160-168	disrupts	_
1-24	169-175	neural	_
1-25	176-184	activity	_
1-26	185-187	in	_
1-27	188-191	the	_
1-28	192-209	mesocorticolimbic	_
1-29	210-216	reward	_
1-30	217-224	network	_
1-31	225-226	;	_
1-32	227-234	however	_
1-33	235-236	,	_
1-34	237-241	less	_
1-35	242-244	is	_
1-36	245-250	known	_
1-37	251-256	about	_
1-38	257-260	the	_
1-39	261-265	time	_
1-40	266-272	course	_
1-41	273-275	of	_
1-42	276-294	abstinence-induced	_
1-43	295-300	brain	_
1-44	301-308	changes	_
1-45	309-310	.	_

Text=To examine the potential neural effects of early abstinence, we used arterial spin labeling perfusion fMRI, to measure regional cerebral blood flow (rCBF) changes in the resting brain induced by 4 h of nicotine abstinence.
2-1	311-313	To	_
2-2	314-321	examine	_
2-3	322-325	the	_
2-4	326-335	potential	_
2-5	336-342	neural	_
2-6	343-350	effects	_
2-7	351-353	of	_
2-8	354-359	early	_
2-9	360-370	abstinence	_
2-10	371-372	,	_
2-11	373-375	we	_
2-12	376-380	used	_
2-13	381-389	arterial	_
2-14	390-394	spin	_
2-15	395-403	labeling	_
2-16	404-413	perfusion	_
2-17	414-418	fMRI	_
2-18	419-420	,	_
2-19	421-423	to	_
2-20	424-431	measure	_
2-21	432-440	regional	_
2-22	441-449	cerebral	_
2-23	450-455	blood	_
2-24	456-460	flow	_
2-25	461-462	(	_
2-26	463-467	rCBF	_
2-27	468-469	)	_
2-28	470-477	changes	_
2-29	478-480	in	_
2-30	481-484	the	_
2-31	485-492	resting	_
2-32	493-498	brain	_
2-33	499-506	induced	_
2-34	507-509	by	_
2-35	510-511	4	_
2-36	512-513	h	_
2-37	514-516	of	_
2-38	517-525	nicotine	_
2-39	526-536	abstinence	_
2-40	537-538	.	_

Text=Methods In a repeated measures design, 5 min of resting perfusion fMRI data were acquired in awake nicotine-dependent individuals (eyes open) during ‘ smoking as usual ’ (SMK) and following 4 h of monitored nicotine abstinence (ABS) conditions (N = 20).
3-1	539-546	Methods	_
3-2	547-549	In	_
3-3	550-551	a	_
3-4	552-560	repeated	_
3-5	561-569	measures	_
3-6	570-576	design	_
3-7	577-578	,	_
3-8	579-580	5	_
3-9	581-584	min	_
3-10	585-587	of	_
3-11	588-595	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-12	596-605	perfusion	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-13	606-610	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-14	611-615	data	_
3-15	616-620	were	_
3-16	621-629	acquired	_
3-17	630-632	in	_
3-18	633-638	awake	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-19	639-657	nicotine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-20	658-669	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-21	670-671	(	_
3-22	672-676	eyes	_
3-23	677-681	open	_
3-24	682-683	)	_
3-25	684-690	during	_
3-26	691-692	‘	_
3-27	693-700	smoking	_
3-28	701-703	as	_
3-29	704-709	usual	_
3-30	710-711	’	_
3-31	712-713	(	_
3-32	714-717	SMK	_
3-33	718-719	)	_
3-34	720-723	and	_
3-35	724-733	following	_
3-36	734-735	4	_
3-37	736-737	h	_
3-38	738-740	of	_
3-39	741-750	monitored	_
3-40	751-759	nicotine	_
3-41	760-770	abstinence	_
3-42	771-772	(	_
3-43	773-776	ABS	_
3-44	777-778	)	_
3-45	779-789	conditions	_
3-46	790-791	(	_
3-47	792-793	N	_
3-48	794-795	=	_
3-49	796-798	20	_
3-50	799-800	)	_
3-51	801-802	.	_

Text=Conditions were compared using a paired t test in SPM8.
4-1	803-813	Conditions	_
4-2	814-818	were	_
4-3	819-827	compared	_
4-4	828-833	using	_
4-5	834-835	a	_
4-6	836-842	paired	_
4-7	843-844	t	_
4-8	845-849	test	_
4-9	850-852	in	_
4-10	853-857	SPM8	_
4-11	858-859	.	_

Text=Craving was assessed prior to each condition.
5-1	860-867	Craving	_
5-2	868-871	was	_
5-3	872-880	assessed	_
5-4	881-886	prior	_
5-5	887-889	to	_
5-6	890-894	each	_
5-7	895-904	condition	_
5-8	905-906	.	_

Text=Results Compared to SMK, ABS significantly increased craving and reduced rCBF in select regions, including the hippocampus and ventral striatum (cluster corr, α = 0.01, 943 contiguous voxels).
6-1	907-914	Results	_
6-2	915-923	Compared	_
6-3	924-926	to	_
6-4	927-930	SMK	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-5	931-932	,	_
6-6	933-936	ABS	_
6-7	937-950	significantly	_
6-8	951-960	increased	_
6-9	961-968	craving	_
6-10	969-972	and	_
6-11	973-980	reduced	_
6-12	981-985	rCBF	_
6-13	986-988	in	_
6-14	989-995	select	_
6-15	996-1003	regions	_
6-16	1004-1005	,	_
6-17	1006-1015	including	_
6-18	1016-1019	the	_
6-19	1020-1031	hippocampus	_
6-20	1032-1035	and	_
6-21	1036-1043	ventral	_
6-22	1044-1052	striatum	_
6-23	1053-1054	(	_
6-24	1055-1062	cluster	_
6-25	1063-1067	corr	_
6-26	1068-1069	,	_
6-27	1070-1071	α	_
6-28	1072-1073	=	_
6-29	1074-1078	0.01	_
6-30	1079-1080	,	_
6-31	1081-1084	943	_
6-32	1085-1095	contiguous	_
6-33	1096-1102	voxels	_
6-34	1103-1104	)	_
6-35	1105-1106	.	_

Text=The magnitude of the abstinence-induced change in rCBF correlated with the magnitude of the change in craving across conditions in select regions, including the medial and lateral orbitofrontal cortices and the anterior ventral insula (r values ranging from 0.59–0.74).
7-1	1107-1110	The	_
7-2	1111-1120	magnitude	_
7-3	1121-1123	of	_
7-4	1124-1127	the	_
7-5	1128-1146	abstinence-induced	_
7-6	1147-1153	change	_
7-7	1154-1156	in	_
7-8	1157-1161	rCBF	_
7-9	1162-1172	correlated	_
7-10	1173-1177	with	_
7-11	1178-1181	the	_
7-12	1182-1191	magnitude	_
7-13	1192-1194	of	_
7-14	1195-1198	the	_
7-15	1199-1205	change	_
7-16	1206-1208	in	_
7-17	1209-1216	craving	_
7-18	1217-1223	across	_
7-19	1224-1234	conditions	_
7-20	1235-1237	in	_
7-21	1238-1244	select	_
7-22	1245-1252	regions	_
7-23	1253-1254	,	_
7-24	1255-1264	including	_
7-25	1265-1268	the	_
7-26	1269-1275	medial	_
7-27	1276-1279	and	_
7-28	1280-1287	lateral	_
7-29	1288-1301	orbitofrontal	_
7-30	1302-1310	cortices	_
7-31	1311-1314	and	_
7-32	1315-1318	the	_
7-33	1319-1327	anterior	_
7-34	1328-1335	ventral	_
7-35	1336-1342	insula	_
7-36	1343-1344	(	_
7-37	1345-1346	r	_
7-38	1347-1353	values	_
7-39	1354-1361	ranging	_
7-40	1362-1366	from	_
7-41	1367-1376	0.59–0.74	_
7-42	1377-1378	)	_
7-43	1379-1380	.	_

Text=Conclusions Results show that as few as 4 h of abstinence can reduce resting rCBF in multiple nodes of the brain ’ s mesocorticolimbic network, disrupting neural processing.
8-1	1381-1392	Conclusions	_
8-2	1393-1400	Results	_
8-3	1401-1405	show	_
8-4	1406-1410	that	_
8-5	1411-1413	as	_
8-6	1414-1417	few	_
8-7	1418-1420	as	_
8-8	1421-1422	4	_
8-9	1423-1424	h	_
8-10	1425-1427	of	_
8-11	1428-1438	abstinence	_
8-12	1439-1442	can	_
8-13	1443-1449	reduce	_
8-14	1450-1457	resting	_
8-15	1458-1462	rCBF	_
8-16	1463-1465	in	_
8-17	1466-1474	multiple	_
8-18	1475-1480	nodes	_
8-19	1481-1483	of	_
8-20	1484-1487	the	_
8-21	1488-1493	brain	_
8-22	1494-1495	’	_
8-23	1496-1497	s	_
8-24	1498-1515	mesocorticolimbic	_
8-25	1516-1523	network	_
8-26	1524-1525	,	_
8-27	1526-1536	disrupting	_
8-28	1537-1543	neural	_
8-29	1544-1554	processing	_
8-30	1555-1556	.	_

Text=Identifying early withdrawal treatment targets has far-reaching implications, which include thwarting relapse proclivities.
9-1	1557-1568	Identifying	_
9-2	1569-1574	early	_
9-3	1575-1585	withdrawal	_
9-4	1586-1595	treatment	_
9-5	1596-1603	targets	_
9-6	1604-1607	has	_
9-7	1608-1620	far-reaching	_
9-8	1621-1633	implications	_
9-9	1634-1635	,	_
9-10	1636-1641	which	_
9-11	1642-1649	include	_
9-12	1650-1659	thwarting	_
9-13	1660-1667	relapse	_
9-14	1668-1680	proclivities	_
9-15	1681-1682	.	_

Text=Results parallel those of the extant human literature and are in agreement with an extensive preclinical literature showing compromised mesolimbic dopaminergic function and impairments in reward function during nicotine withdrawal.
10-1	1683-1690	Results	_
10-2	1691-1699	parallel	_
10-3	1700-1705	those	_
10-4	1706-1708	of	_
10-5	1709-1712	the	_
10-6	1713-1719	extant	_
10-7	1720-1725	human	_
10-8	1726-1736	literature	_
10-9	1737-1740	and	_
10-10	1741-1744	are	_
10-11	1745-1747	in	_
10-12	1748-1757	agreement	_
10-13	1758-1762	with	_
10-14	1763-1765	an	_
10-15	1766-1775	extensive	_
10-16	1776-1787	preclinical	_
10-17	1788-1798	literature	_
10-18	1799-1806	showing	_
10-19	1807-1818	compromised	_
10-20	1819-1829	mesolimbic	_
10-21	1830-1842	dopaminergic	_
10-22	1843-1851	function	_
10-23	1852-1855	and	_
10-24	1856-1867	impairments	_
10-25	1868-1870	in	_
10-26	1871-1877	reward	_
10-27	1878-1886	function	_
10-28	1887-1893	during	_
10-29	1894-1902	nicotine	_
10-30	1903-1913	withdrawal	_
10-31	1914-1915	.	_

Text=2.
11-1	1916-1917	2	_
11-2	1918-1919	.	_

Text=Methods 2.1.
12-1	1920-1927	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1928-1931	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1932-1933	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=Participants The study was conducted at the University of Pennsylvania Perelman School of Medicine.
13-1	1934-1946	Participants	_
13-2	1947-1950	The	_
13-3	1951-1956	study	_
13-4	1957-1960	was	_
13-5	1961-1970	conducted	_
13-6	1971-1973	at	_
13-7	1974-1977	the	_
13-8	1978-1988	University	_
13-9	1989-1991	of	_
13-10	1992-2004	Pennsylvania	_
13-11	2005-2013	Perelman	_
13-12	2014-2020	School	_
13-13	2021-2023	of	_
13-14	2024-2032	Medicine	_
13-15	2033-2034	.	_

Text=All procedures were approved and monitored by the Institutional Review Board, and adhered to the Declaration of Helsinki.
14-1	2035-2038	All	_
14-2	2039-2049	procedures	_
14-3	2050-2054	were	_
14-4	2055-2063	approved	_
14-5	2064-2067	and	_
14-6	2068-2077	monitored	_
14-7	2078-2080	by	_
14-8	2081-2084	the	_
14-9	2085-2098	Institutional	_
14-10	2099-2105	Review	_
14-11	2106-2111	Board	_
14-12	2112-2113	,	_
14-13	2114-2117	and	_
14-14	2118-2125	adhered	_
14-15	2126-2128	to	_
14-16	2129-2132	the	_
14-17	2133-2144	Declaration	_
14-18	2145-2147	of	_
14-19	2148-2156	Helsinki	_
14-20	2157-2158	.	_

Text=Participants received compensation ranging from $235 to $250 for participating in the study.
15-1	2159-2171	Participants	_
15-2	2172-2180	received	_
15-3	2181-2193	compensation	_
15-4	2194-2201	ranging	_
15-5	2202-2206	from	_
15-6	2207-2208	$	_
15-7	2209-2212	235	_
15-8	2213-2215	to	_
15-9	2216-2217	$	_
15-10	2218-2221	250	_
15-11	2222-2225	for	_
15-12	2226-2239	participating	_
15-13	2240-2242	in	_
15-14	2243-2246	the	_
15-15	2247-2252	study	_
15-16	2253-2254	.	_

Text=Eligible participants were non-treatment-seeking smokers (18–60 years of age) who reported smoking at least 10 cigarettes per day for the past 3 years and had baseline carbon monoxide (CO) levels greater than 10 ppm.
16-1	2255-2263	Eligible	_
16-2	2264-2276	participants	_
16-3	2277-2281	were	_
16-4	2282-2303	non-treatment-seeking	_
16-5	2304-2311	smokers	_
16-6	2312-2313	(	_
16-7	2314-2319	18–60	_
16-8	2320-2325	years	_
16-9	2326-2328	of	_
16-10	2329-2332	age	_
16-11	2333-2334	)	_
16-12	2335-2338	who	_
16-13	2339-2347	reported	_
16-14	2348-2355	smoking	_
16-15	2356-2358	at	_
16-16	2359-2364	least	_
16-17	2365-2367	10	_
16-18	2368-2378	cigarettes	_
16-19	2379-2382	per	_
16-20	2383-2386	day	_
16-21	2387-2390	for	_
16-22	2391-2394	the	_
16-23	2395-2399	past	_
16-24	2400-2401	3	_
16-25	2402-2407	years	_
16-26	2408-2411	and	_
16-27	2412-2415	had	_
16-28	2416-2424	baseline	_
16-29	2425-2431	carbon	_
16-30	2432-2440	monoxide	_
16-31	2441-2442	(	_
16-32	2443-2445	CO	_
16-33	2446-2447	)	_
16-34	2448-2454	levels	_
16-35	2455-2462	greater	_
16-36	2463-2467	than	_
16-37	2468-2470	10	_
16-38	2471-2474	ppm	_
16-39	2475-2476	.	_

Text=Ten CPD was chosen as the smoking criteria to study the effects of 4 h of abstinence because 1) 10 CPD represents the average smoker in the current climate, wherein smoking is largely prohibited in the work place and most other public places in the U.S; 2) a 10 CPD individual scores in the range of moderate nicotine dependence on the FTND; and 3) ten CPD corresponds to approximately a little over 1 cigarette over the course of two hours in a 16 h day (assuming 8 h are spent sleeping), thus such an individual is likely to experience some symptoms of withdrawal in the absence of nicotine over a 4-h period.
17-1	2477-2480	Ten	_
17-2	2481-2484	CPD	_
17-3	2485-2488	was	_
17-4	2489-2495	chosen	_
17-5	2496-2498	as	_
17-6	2499-2502	the	_
17-7	2503-2510	smoking	_
17-8	2511-2519	criteria	_
17-9	2520-2522	to	_
17-10	2523-2528	study	_
17-11	2529-2532	the	_
17-12	2533-2540	effects	_
17-13	2541-2543	of	_
17-14	2544-2545	4	_
17-15	2546-2547	h	_
17-16	2548-2550	of	_
17-17	2551-2561	abstinence	_
17-18	2562-2569	because	_
17-19	2570-2571	1	_
17-20	2572-2573	)	_
17-21	2574-2576	10	_
17-22	2577-2580	CPD	_
17-23	2581-2591	represents	_
17-24	2592-2595	the	_
17-25	2596-2603	average	_
17-26	2604-2610	smoker	_
17-27	2611-2613	in	_
17-28	2614-2617	the	_
17-29	2618-2625	current	_
17-30	2626-2633	climate	_
17-31	2634-2635	,	_
17-32	2636-2643	wherein	_
17-33	2644-2651	smoking	_
17-34	2652-2654	is	_
17-35	2655-2662	largely	_
17-36	2663-2673	prohibited	_
17-37	2674-2676	in	_
17-38	2677-2680	the	_
17-39	2681-2685	work	_
17-40	2686-2691	place	_
17-41	2692-2695	and	_
17-42	2696-2700	most	_
17-43	2701-2706	other	_
17-44	2707-2713	public	_
17-45	2714-2720	places	_
17-46	2721-2723	in	_
17-47	2724-2727	the	_
17-48	2728-2731	U.S	_
17-49	2732-2733	;	_
17-50	2734-2735	2	_
17-51	2736-2737	)	_
17-52	2738-2739	a	_
17-53	2740-2742	10	_
17-54	2743-2746	CPD	_
17-55	2747-2757	individual	_
17-56	2758-2764	scores	_
17-57	2765-2767	in	_
17-58	2768-2771	the	_
17-59	2772-2777	range	_
17-60	2778-2780	of	_
17-61	2781-2789	moderate	_
17-62	2790-2798	nicotine	_
17-63	2799-2809	dependence	_
17-64	2810-2812	on	_
17-65	2813-2816	the	_
17-66	2817-2821	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
17-67	2822-2823	;	_
17-68	2824-2827	and	_
17-69	2828-2829	3	_
17-70	2830-2831	)	_
17-71	2832-2835	ten	_
17-72	2836-2839	CPD	_
17-73	2840-2851	corresponds	_
17-74	2852-2854	to	_
17-75	2855-2868	approximately	_
17-76	2869-2870	a	_
17-77	2871-2877	little	_
17-78	2878-2882	over	_
17-79	2883-2884	1	_
17-80	2885-2894	cigarette	_
17-81	2895-2899	over	_
17-82	2900-2903	the	_
17-83	2904-2910	course	_
17-84	2911-2913	of	_
17-85	2914-2917	two	_
17-86	2918-2923	hours	_
17-87	2924-2926	in	_
17-88	2927-2928	a	_
17-89	2929-2931	16	_
17-90	2932-2933	h	_
17-91	2934-2937	day	_
17-92	2938-2939	(	_
17-93	2940-2948	assuming	_
17-94	2949-2950	8	_
17-95	2951-2952	h	_
17-96	2953-2956	are	_
17-97	2957-2962	spent	_
17-98	2963-2971	sleeping	_
17-99	2972-2973	)	_
17-100	2974-2975	,	_
17-101	2976-2980	thus	_
17-102	2981-2985	such	_
17-103	2986-2988	an	_
17-104	2989-2999	individual	_
17-105	3000-3002	is	_
17-106	3003-3009	likely	_
17-107	3010-3012	to	_
17-108	3013-3023	experience	_
17-109	3024-3028	some	_
17-110	3029-3037	symptoms	_
17-111	3038-3040	of	_
17-112	3041-3051	withdrawal	_
17-113	3052-3054	in	_
17-114	3055-3058	the	_
17-115	3059-3066	absence	_
17-116	3067-3069	of	_
17-117	3070-3078	nicotine	_
17-118	3079-3083	over	_
17-119	3084-3085	a	_
17-120	3086-3089	4-h	_
17-121	3090-3096	period	_
17-122	3097-3098	.	_

Text=Participants were screened, tested on study knowledge, and consented prior to study participation.
18-1	3099-3111	Participants	_
18-2	3112-3116	were	_
18-3	3117-3125	screened	_
18-4	3126-3127	,	_
18-5	3128-3134	tested	_
18-6	3135-3137	on	_
18-7	3138-3143	study	_
18-8	3144-3153	knowledge	_
18-9	3154-3155	,	_
18-10	3156-3159	and	_
18-11	3160-3169	consented	_
18-12	3170-3175	prior	_
18-13	3176-3178	to	_
18-14	3179-3184	study	_
18-15	3185-3198	participation	_
18-16	3199-3200	.	_

Text=Severity of nicotine dependence was determined from the Fagerström Test for Nicotine Dependence (FTND).
19-1	3201-3209	Severity	_
19-2	3210-3212	of	_
19-3	3213-3221	nicotine	_
19-4	3222-3232	dependence	_
19-5	3233-3236	was	_
19-6	3237-3247	determined	_
19-7	3248-3252	from	_
19-8	3253-3256	the	_
19-9	3257-3267	Fagerström	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-10	3268-3272	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-11	3273-3276	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-12	3277-3285	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-13	3286-3296	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-14	3297-3298	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-15	3299-3303	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-16	3304-3305	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-17	3306-3307	.	_

Text=Exclusion criteria included current substance use disorder, positive urine drug screen for illicit drugs (tested at screening and prior to MRI sessions), seeking treatment for cigarette/nicotine dependence or attempting to quit smoking, having an acute, chronic or debilitating medical condition, psychiatric disorders as determined by The MINI International Neuropsychiatric Interview, a history of head trauma or other injury resulting in loss of consciousness lasting greater than three minutes or associated with skull fracture or intra-cranial bleeding, and other contraindications for MRI, and head movement of more than 1.5 mm over the course of the resting baseline acquisition.
20-1	3308-3317	Exclusion	_
20-2	3318-3326	criteria	_
20-3	3327-3335	included	_
20-4	3336-3343	current	_
20-5	3344-3353	substance	_
20-6	3354-3357	use	_
20-7	3358-3366	disorder	_
20-8	3367-3368	,	_
20-9	3369-3377	positive	_
20-10	3378-3383	urine	_
20-11	3384-3388	drug	_
20-12	3389-3395	screen	_
20-13	3396-3399	for	_
20-14	3400-3407	illicit	_
20-15	3408-3413	drugs	_
20-16	3414-3415	(	_
20-17	3416-3422	tested	_
20-18	3423-3425	at	_
20-19	3426-3435	screening	_
20-20	3436-3439	and	_
20-21	3440-3445	prior	_
20-22	3446-3448	to	_
20-23	3449-3452	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-24	3453-3461	sessions	_
20-25	3462-3463	)	_
20-26	3464-3465	,	_
20-27	3466-3473	seeking	_
20-28	3474-3483	treatment	_
20-29	3484-3487	for	_
20-30	3488-3506	cigarette/nicotine	_
20-31	3507-3517	dependence	_
20-32	3518-3520	or	_
20-33	3521-3531	attempting	_
20-34	3532-3534	to	_
20-35	3535-3539	quit	_
20-36	3540-3547	smoking	_
20-37	3548-3549	,	_
20-38	3550-3556	having	_
20-39	3557-3559	an	_
20-40	3560-3565	acute	_
20-41	3566-3567	,	_
20-42	3568-3575	chronic	_
20-43	3576-3578	or	_
20-44	3579-3591	debilitating	_
20-45	3592-3599	medical	_
20-46	3600-3609	condition	_
20-47	3610-3611	,	_
20-48	3612-3623	psychiatric	_
20-49	3624-3633	disorders	_
20-50	3634-3636	as	_
20-51	3637-3647	determined	_
20-52	3648-3650	by	_
20-53	3651-3654	The	_
20-54	3655-3659	MINI	_
20-55	3660-3673	International	_
20-56	3674-3690	Neuropsychiatric	_
20-57	3691-3700	Interview	_
20-58	3701-3702	,	_
20-59	3703-3704	a	_
20-60	3705-3712	history	_
20-61	3713-3715	of	_
20-62	3716-3720	head	_
20-63	3721-3727	trauma	_
20-64	3728-3730	or	_
20-65	3731-3736	other	_
20-66	3737-3743	injury	_
20-67	3744-3753	resulting	_
20-68	3754-3756	in	_
20-69	3757-3761	loss	_
20-70	3762-3764	of	_
20-71	3765-3778	consciousness	_
20-72	3779-3786	lasting	_
20-73	3787-3794	greater	_
20-74	3795-3799	than	_
20-75	3800-3805	three	_
20-76	3806-3813	minutes	_
20-77	3814-3816	or	_
20-78	3817-3827	associated	_
20-79	3828-3832	with	_
20-80	3833-3838	skull	_
20-81	3839-3847	fracture	_
20-82	3848-3850	or	_
20-83	3851-3864	intra-cranial	_
20-84	3865-3873	bleeding	_
20-85	3874-3875	,	_
20-86	3876-3879	and	_
20-87	3880-3885	other	_
20-88	3886-3903	contraindications	_
20-89	3904-3907	for	_
20-90	3908-3911	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
20-91	3912-3913	,	_
20-92	3914-3917	and	_
20-93	3918-3922	head	_
20-94	3923-3931	movement	_
20-95	3932-3934	of	_
20-96	3935-3939	more	_
20-97	3940-3944	than	_
20-98	3945-3948	1.5	_
20-99	3949-3951	mm	_
20-100	3952-3956	over	_
20-101	3957-3960	the	_
20-102	3961-3967	course	_
20-103	3968-3970	of	_
20-104	3971-3974	the	_
20-105	3975-3982	resting	_
20-106	3983-3991	baseline	_
20-107	3992-4003	acquisition	_
20-108	4004-4005	.	_

Text=Following MRI acquisition, participants with abnormal structural MRIs were excluded (N = 2), leaving 20 eligible participants.
21-1	4006-4015	Following	_
21-2	4016-4019	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-3	4020-4031	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-4	4032-4033	,	_
21-5	4034-4046	participants	_
21-6	4047-4051	with	_
21-7	4052-4060	abnormal	_
21-8	4061-4071	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-9	4072-4076	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-10	4077-4081	were	_
21-11	4082-4090	excluded	_
21-12	4091-4092	(	_
21-13	4093-4094	N	_
21-14	4095-4096	=	_
21-15	4097-4098	2	_
21-16	4099-4100	)	_
21-17	4101-4102	,	_
21-18	4103-4110	leaving	_
21-19	4111-4113	20	_
21-20	4114-4122	eligible	_
21-21	4123-4135	participants	_
21-22	4136-4137	.	_

Text=Eligible participants were 50% male and the majority (80%) were White.
22-1	4138-4146	Eligible	_
22-2	4147-4159	participants	_
22-3	4160-4164	were	_
22-4	4165-4167	50	_
22-5	4168-4169	%	_
22-6	4170-4174	male	_
22-7	4175-4178	and	_
22-8	4179-4182	the	_
22-9	4183-4191	majority	_
22-10	4192-4193	(	_
22-11	4194-4196	80	_
22-12	4197-4198	%	_
22-13	4199-4200	)	_
22-14	4201-4205	were	_
22-15	4206-4211	White	_
22-16	4212-4213	.	_

Text=Other races included 1 Black, 2 Multiple Ethnicity, and 1 Asian.
23-1	4214-4219	Other	_
23-2	4220-4225	races	_
23-3	4226-4234	included	_
23-4	4235-4236	1	_
23-5	4237-4242	Black	_
23-6	4243-4244	,	_
23-7	4245-4246	2	_
23-8	4247-4255	Multiple	_
23-9	4256-4265	Ethnicity	_
23-10	4266-4267	,	_
23-11	4268-4271	and	_
23-12	4272-4273	1	_
23-13	4274-4279	Asian	_
23-14	4280-4281	.	_

Text=Participants were 29.1 ± 2.13 years of age, having 14.75 ± 0.52 years of education.
24-1	4282-4294	Participants	_
24-2	4295-4299	were	_
24-3	4300-4304	29.1	_
24-4	4305-4306	±	_
24-5	4307-4311	2.13	_
24-6	4312-4317	years	_
24-7	4318-4320	of	_
24-8	4321-4324	age	_
24-9	4325-4326	,	_
24-10	4327-4333	having	_
24-11	4334-4339	14.75	_
24-12	4340-4341	±	_
24-13	4342-4346	0.52	_
24-14	4347-4352	years	_
24-15	4353-4355	of	_
24-16	4356-4365	education	_
24-17	4366-4367	.	_

Text=Participants smoked 15.
25-1	4368-4380	Participants	_
25-2	4381-4387	smoked	_
25-3	4388-4390	15	_
25-4	4391-4392	.	_

Text=± 1.13 cigarettes per day for 11.0 ± 1.87 years (range: 3–33 years), and scored 4.18 ± 0.37 on the FTND (indicating moderate nicotine dependence).
26-1	4393-4394	±	_
26-2	4395-4399	1.13	_
26-3	4400-4410	cigarettes	_
26-4	4411-4414	per	_
26-5	4415-4418	day	_
26-6	4419-4422	for	_
26-7	4423-4427	11.0	_
26-8	4428-4429	±	_
26-9	4430-4434	1.87	_
26-10	4435-4440	years	_
26-11	4441-4442	(	_
26-12	4443-4448	range	_
26-13	4449-4450	:	_
26-14	4451-4455	3–33	_
26-15	4456-4461	years	_
26-16	4462-4463	)	_
26-17	4464-4465	,	_
26-18	4466-4469	and	_
26-19	4470-4476	scored	_
26-20	4477-4481	4.18	_
26-21	4482-4483	±	_
26-22	4484-4488	0.37	_
26-23	4489-4491	on	_
26-24	4492-4495	the	_
26-25	4496-4500	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
26-26	4501-4502	(	_
26-27	4503-4513	indicating	_
26-28	4514-4522	moderate	_
26-29	4523-4531	nicotine	_
26-30	4532-4542	dependence	_
26-31	4543-4544	)	_
26-32	4545-4546	.	_

Text=2.2.
27-1	4547-4550	2.2	_
27-2	4551-4552	.	_

Text=Experimental design Participants participated in two scanning sessions that occurred on separate days at least 3 or more days apart.
28-1	4553-4565	Experimental	_
28-2	4566-4572	design	_
28-3	4573-4585	Participants	_
28-4	4586-4598	participated	_
28-5	4599-4601	in	_
28-6	4602-4605	two	_
28-7	4606-4614	scanning	_
28-8	4615-4623	sessions	_
28-9	4624-4628	that	_
28-10	4629-4637	occurred	_
28-11	4638-4640	on	_
28-12	4641-4649	separate	_
28-13	4650-4654	days	_
28-14	4655-4657	at	_
28-15	4658-4663	least	_
28-16	4664-4665	3	_
28-17	4666-4668	or	_
28-18	4669-4673	more	_
28-19	4674-4678	days	_
28-20	4679-4684	apart	_
28-21	4685-4686	.	_

Text=The abstinent scan was conducted following 4 h of staff- and CO-monitored nicotine abstinence.
29-1	4687-4690	The	_
29-2	4691-4700	abstinent	_
29-3	4701-4705	scan	_
29-4	4706-4709	was	_
29-5	4710-4719	conducted	_
29-6	4720-4729	following	_
29-7	4730-4731	4	_
29-8	4732-4733	h	_
29-9	4734-4736	of	_
29-10	4737-4743	staff-	_
29-11	4744-4747	and	_
29-12	4748-4760	CO-monitored	_
29-13	4761-4769	nicotine	_
29-14	4770-4780	abstinence	_
29-15	4781-4782	.	_

Text=Prior to the monitored abstinence (ABS) regimen, participants smoked a cigarette to satiety to standardize time since last smoked (i.e., ∼ 4 h prior to MRI data acquisition) In the ‘ smoking as usual ’ (SMK) condition, participants smoked throughout the day ad lib, were monitored for 2 h prior to scanning while continuing to smoke ad lib, and smoked to satiety 20–25 min prior to acquisition of the resting baseline CBF data to standardize time since last smoked and ensure dissipation of the acute cardiovascular effects of smoking.
30-1	4783-4788	Prior	_
30-2	4789-4791	to	_
30-3	4792-4795	the	_
30-4	4796-4805	monitored	_
30-5	4806-4816	abstinence	_
30-6	4817-4818	(	_
30-7	4819-4822	ABS	_
30-8	4823-4824	)	_
30-9	4825-4832	regimen	_
30-10	4833-4834	,	_
30-11	4835-4847	participants	_
30-12	4848-4854	smoked	_
30-13	4855-4856	a	_
30-14	4857-4866	cigarette	_
30-15	4867-4869	to	_
30-16	4870-4877	satiety	_
30-17	4878-4880	to	_
30-18	4881-4892	standardize	_
30-19	4893-4897	time	_
30-20	4898-4903	since	_
30-21	4904-4908	last	_
30-22	4909-4915	smoked	_
30-23	4916-4917	(	_
30-24	4918-4922	i.e.	_
30-25	4923-4924	,	_
30-26	4925-4926	∼	_
30-27	4927-4928	4	_
30-28	4929-4930	h	_
30-29	4931-4936	prior	_
30-30	4937-4939	to	_
30-31	4940-4943	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
30-32	4944-4948	data	_
30-33	4949-4960	acquisition	_
30-34	4961-4962	)	_
30-35	4963-4965	In	_
30-36	4966-4969	the	_
30-37	4970-4971	‘	_
30-38	4972-4979	smoking	_
30-39	4980-4982	as	_
30-40	4983-4988	usual	_
30-41	4989-4990	’	_
30-42	4991-4992	(	_
30-43	4993-4996	SMK	_
30-44	4997-4998	)	_
30-45	4999-5008	condition	_
30-46	5009-5010	,	_
30-47	5011-5023	participants	_
30-48	5024-5030	smoked	_
30-49	5031-5041	throughout	_
30-50	5042-5045	the	_
30-51	5046-5049	day	_
30-52	5050-5052	ad	_
30-53	5053-5056	lib	_
30-54	5057-5058	,	_
30-55	5059-5063	were	_
30-56	5064-5073	monitored	_
30-57	5074-5077	for	_
30-58	5078-5079	2	_
30-59	5080-5081	h	_
30-60	5082-5087	prior	_
30-61	5088-5090	to	_
30-62	5091-5099	scanning	_
30-63	5100-5105	while	_
30-64	5106-5116	continuing	_
30-65	5117-5119	to	_
30-66	5120-5125	smoke	_
30-67	5126-5128	ad	_
30-68	5129-5132	lib	_
30-69	5133-5134	,	_
30-70	5135-5138	and	_
30-71	5139-5145	smoked	_
30-72	5146-5148	to	_
30-73	5149-5156	satiety	_
30-74	5157-5162	20–25	_
30-75	5163-5166	min	_
30-76	5167-5172	prior	_
30-77	5173-5175	to	_
30-78	5176-5187	acquisition	_
30-79	5188-5190	of	_
30-80	5191-5194	the	_
30-81	5195-5202	resting	_
30-82	5203-5211	baseline	_
30-83	5212-5215	CBF	_
30-84	5216-5220	data	_
30-85	5221-5223	to	_
30-86	5224-5235	standardize	_
30-87	5236-5240	time	_
30-88	5241-5246	since	_
30-89	5247-5251	last	_
30-90	5252-5258	smoked	_
30-91	5259-5262	and	_
30-92	5263-5269	ensure	_
30-93	5270-5281	dissipation	_
30-94	5282-5284	of	_
30-95	5285-5288	the	_
30-96	5289-5294	acute	_
30-97	5295-5309	cardiovascular	_
30-98	5310-5317	effects	_
30-99	5318-5320	of	_
30-100	5321-5328	smoking	_
30-101	5329-5330	.	_

Text=During the monitoring period, participants were occupied similarly, filling out questionnaires and participating in various computer tasks.
31-1	5331-5337	During	_
31-2	5338-5341	the	_
31-3	5342-5352	monitoring	_
31-4	5353-5359	period	_
31-5	5360-5361	,	_
31-6	5362-5374	participants	_
31-7	5375-5379	were	_
31-8	5380-5388	occupied	_
31-9	5389-5398	similarly	_
31-10	5399-5400	,	_
31-11	5401-5408	filling	_
31-12	5409-5412	out	_
31-13	5413-5427	questionnaires	_
31-14	5428-5431	and	_
31-15	5432-5445	participating	_
31-16	5446-5448	in	_
31-17	5449-5456	various	_
31-18	5457-5465	computer	_
31-19	5466-5471	tasks	_
31-20	5472-5473	.	_

Text=Subjective reports of cigarette craving and withdrawal were obtained prior to each condition using the Craving and Withdrawal Questionnaire (CWQ) and, in a subset of subjects, the Shiffman-Jarvik Scale was also acquired (n = 14; due to technical error, the Shiffman-Jarvik was omitted from one or both scanning sessions in 6 subjects).
32-1	5474-5484	Subjective	_
32-2	5485-5492	reports	_
32-3	5493-5495	of	_
32-4	5496-5505	cigarette	_
32-5	5506-5513	craving	_
32-6	5514-5517	and	_
32-7	5518-5528	withdrawal	_
32-8	5529-5533	were	_
32-9	5534-5542	obtained	_
32-10	5543-5548	prior	_
32-11	5549-5551	to	_
32-12	5552-5556	each	_
32-13	5557-5566	condition	_
32-14	5567-5572	using	_
32-15	5573-5576	the	_
32-16	5577-5584	Craving	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-17	5585-5588	and	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-18	5589-5599	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-19	5600-5613	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-20	5614-5615	(	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-21	5616-5619	CWQ	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-22	5620-5621	)	http://maven.renci.org/NeuroBridge/neurobridge#Questionnaire
32-23	5622-5625	and	_
32-24	5626-5627	,	_
32-25	5628-5630	in	_
32-26	5631-5632	a	_
32-27	5633-5639	subset	_
32-28	5640-5642	of	_
32-29	5643-5651	subjects	_
32-30	5652-5653	,	_
32-31	5654-5657	the	_
32-32	5658-5673	Shiffman-Jarvik	http://maven.renci.org/NeuroBridge/neurobridge#Scale
32-33	5674-5679	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
32-34	5680-5683	was	_
32-35	5684-5688	also	_
32-36	5689-5697	acquired	_
32-37	5698-5699	(	_
32-38	5700-5701	n	_
32-39	5702-5703	=	_
32-40	5704-5706	14	_
32-41	5707-5708	;	_
32-42	5709-5712	due	_
32-43	5713-5715	to	_
32-44	5716-5725	technical	_
32-45	5726-5731	error	_
32-46	5732-5733	,	_
32-47	5734-5737	the	_
32-48	5738-5753	Shiffman-Jarvik	_
32-49	5754-5757	was	_
32-50	5758-5765	omitted	_
32-51	5766-5770	from	_
32-52	5771-5774	one	_
32-53	5775-5777	or	_
32-54	5778-5782	both	_
32-55	5783-5791	scanning	_
32-56	5792-5800	sessions	_
32-57	5801-5803	in	_
32-58	5804-5805	6	_
32-59	5806-5814	subjects	_
32-60	5815-5816	)	_
32-61	5817-5818	.	_

Text=Sessions were counterbalanced such that half the participants were scanned in the ABS condition first and half were scanned in the SMK condition first.
33-1	5819-5827	Sessions	_
33-2	5828-5832	were	_
33-3	5833-5848	counterbalanced	_
33-4	5849-5853	such	_
33-5	5854-5858	that	_
33-6	5859-5863	half	_
33-7	5864-5867	the	_
33-8	5868-5880	participants	_
33-9	5881-5885	were	_
33-10	5886-5893	scanned	_
33-11	5894-5896	in	_
33-12	5897-5900	the	_
33-13	5901-5904	ABS	_
33-14	5905-5914	condition	_
33-15	5915-5920	first	_
33-16	5921-5924	and	_
33-17	5925-5929	half	_
33-18	5930-5934	were	_
33-19	5935-5942	scanned	_
33-20	5943-5945	in	_
33-21	5946-5949	the	_
33-22	5950-5953	SMK	_
33-23	5954-5963	condition	_
33-24	5964-5969	first	_
33-25	5970-5971	.	_

Text=For each session, a high-resolution structural scan was acquired first, followed by the resting pseudo continuous arterial spin labeled (pCASL) perfusion fMRI scan.
34-1	5972-5975	For	_
34-2	5976-5980	each	_
34-3	5981-5988	session	_
34-4	5989-5990	,	_
34-5	5991-5992	a	_
34-6	5993-6008	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
34-7	6009-6019	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
34-8	6020-6024	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
34-9	6025-6028	was	_
34-10	6029-6037	acquired	_
34-11	6038-6043	first	_
34-12	6044-6045	,	_
34-13	6046-6054	followed	_
34-14	6055-6057	by	_
34-15	6058-6061	the	_
34-16	6062-6069	resting	_
34-17	6070-6076	pseudo	_
34-18	6077-6087	continuous	_
34-19	6088-6096	arterial	_
34-20	6097-6101	spin	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-21	6102-6109	labeled	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-22	6110-6111	(	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-23	6112-6117	pCASL	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-24	6118-6119	)	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-25	6120-6129	perfusion	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-26	6130-6134	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-27	6135-6139	scan	http://maven.renci.org/NeuroBridge/neurobridge#PerfusionImagingProtocol
34-28	6140-6141	.	_

Text=Although not the focus of the current investigation, additional scans were acquired subsequently.
35-1	6142-6150	Although	_
35-2	6151-6154	not	_
35-3	6155-6158	the	_
35-4	6159-6164	focus	_
35-5	6165-6167	of	_
35-6	6168-6171	the	_
35-7	6172-6179	current	_
35-8	6180-6193	investigation	_
35-9	6194-6195	,	_
35-10	6196-6206	additional	_
35-11	6207-6212	scans	_
35-12	6213-6217	were	_
35-13	6218-6226	acquired	_
35-14	6227-6239	subsequently	_
35-15	6240-6241	.	_

Text=Throughout the scanning session, participants were instructed to lie still in the scanner with their eyes open.
36-1	6242-6252	Throughout	_
36-2	6253-6256	the	_
36-3	6257-6265	scanning	_
36-4	6266-6273	session	_
36-5	6274-6275	,	_
36-6	6276-6288	participants	_
36-7	6289-6293	were	_
36-8	6294-6304	instructed	_
36-9	6305-6307	to	_
36-10	6308-6311	lie	_
36-11	6312-6317	still	_
36-12	6318-6320	in	_
36-13	6321-6324	the	_
36-14	6325-6332	scanner	_
36-15	6333-6337	with	_
36-16	6338-6343	their	_
36-17	6344-6348	eyes	_
36-18	6349-6353	open	_
36-19	6354-6355	.	_

Text=Wakefulness was verified by monitoring with a MR-compatible video camera (MRC Systems; http: //www.mrc-systems.de).
37-1	6356-6367	Wakefulness	_
37-2	6368-6371	was	_
37-3	6372-6380	verified	_
37-4	6381-6383	by	_
37-5	6384-6394	monitoring	_
37-6	6395-6399	with	_
37-7	6400-6401	a	_
37-8	6402-6415	MR-compatible	_
37-9	6416-6421	video	_
37-10	6422-6428	camera	_
37-11	6429-6430	(	_
37-12	6431-6434	MRC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
37-13	6435-6442	Systems	_
37-14	6443-6444	;	_
37-15	6445-6449	http	_
37-16	6450-6451	:	_
37-17	6452-6472	//www.mrc-systems.de	_
37-18	6473-6474	)	_
37-19	6475-6476	.	_

Text=2.3.
38-1	6477-6480	2.3	_
38-2	6481-6482	.	_

Text=MRI data acquisition MRI data were acquired on a Siemens 3.0 T Trio whole-body scanner (Siemens AG, Erlangen, Germany) using a standard 8-channel receive-only array head coil.
39-1	6483-6486	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-2	6487-6491	data	_
39-3	6492-6503	acquisition	_
39-4	6504-6507	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-5	6508-6512	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-6	6513-6517	were	_
39-7	6518-6526	acquired	_
39-8	6527-6529	on	_
39-9	6530-6531	a	_
39-10	6532-6539	Siemens	_
39-11	6540-6543	3.0	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
39-12	6544-6545	T	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
39-13	6546-6550	Trio	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
39-14	6551-6561	whole-body	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
39-15	6562-6569	scanner	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
39-16	6570-6571	(	_
39-17	6572-6579	Siemens	_
39-18	6580-6582	AG	_
39-19	6583-6584	,	_
39-20	6585-6593	Erlangen	_
39-21	6594-6595	,	_
39-22	6596-6603	Germany	_
39-23	6604-6605	)	_
39-24	6606-6611	using	_
39-25	6612-6613	a	_
39-26	6614-6622	standard	_
39-27	6623-6632	8-channel	_
39-28	6633-6645	receive-only	_
39-29	6646-6651	array	_
39-30	6652-6656	head	_
39-31	6657-6661	coil	_
39-32	6662-6663	.	_

Text=High-resolution anatomical images were obtained for co-registration using a standard 3-dimensional (3D) Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE) sequence with TR = 1620 ms, time to inversion (TI) = 950 ms, echo time (TE) = 3 ms, flip angle = 15°, 160 contiguous slices, 1 × 1 × 1 mm resolution.
40-1	6664-6679	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
40-2	6680-6690	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
40-3	6691-6697	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
40-4	6698-6702	were	_
40-5	6703-6711	obtained	_
40-6	6712-6715	for	_
40-7	6716-6731	co-registration	_
40-8	6732-6737	using	_
40-9	6738-6739	a	_
40-10	6740-6748	standard	_
40-11	6749-6762	3-dimensional	_
40-12	6763-6764	(	_
40-13	6765-6767	3D	_
40-14	6768-6769	)	http://maven.renci.org/NeuroBridge/neurobridge#Organization
40-15	6770-6783	Magnetization	http://maven.renci.org/NeuroBridge/neurobridge#Organization
40-16	6784-6792	Prepared	_
40-17	6793-6798	Rapid	_
40-18	6799-6810	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-19	6811-6819	Gradient	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-20	6820-6824	Echo	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-21	6825-6826	(	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-22	6827-6833	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-23	6834-6835	)	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-24	6836-6844	sequence	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodExperienceofCareandAbuseQuestionnaire
40-25	6845-6849	with	_
40-26	6850-6852	TR	_
40-27	6853-6854	=	_
40-28	6855-6859	1620	_
40-29	6860-6862	ms	_
40-30	6863-6864	,	_
40-31	6865-6869	time	_
40-32	6870-6872	to	_
40-33	6873-6882	inversion	_
40-34	6883-6884	(	_
40-35	6885-6887	TI	_
40-36	6888-6889	)	_
40-37	6890-6891	=	_
40-38	6892-6895	950	_
40-39	6896-6898	ms	_
40-40	6899-6900	,	_
40-41	6901-6905	echo	_
40-42	6906-6910	time	_
40-43	6911-6912	(	_
40-44	6913-6915	TE	_
40-45	6916-6917	)	_
40-46	6918-6919	=	_
40-47	6920-6921	3	_
40-48	6922-6924	ms	_
40-49	6925-6926	,	_
40-50	6927-6931	flip	_
40-51	6932-6937	angle	_
40-52	6938-6939	=	_
40-53	6940-6943	15°	_
40-54	6944-6945	,	_
40-55	6946-6949	160	_
40-56	6950-6960	contiguous	_
40-57	6961-6967	slices	_
40-58	6968-6969	,	_
40-59	6970-6971	1	_
40-60	6972-6973	×	_
40-61	6974-6975	1	_
40-62	6976-6977	×	_
40-63	6978-6979	1	_
40-64	6980-6982	mm	_
40-65	6983-6993	resolution	_
40-66	6994-6995	.	_

Text=The MPRAGE sequence was 5 min in duration.
41-1	6996-6999	The	_
41-2	7000-7006	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
41-3	7007-7015	sequence	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
41-4	7016-7019	was	_
41-5	7020-7021	5	_
41-6	7022-7025	min	_
41-7	7026-7028	in	_
41-8	7029-7037	duration	_
41-9	7038-7039	.	_

Text=Following acquisition of the structural scans, ASL perfusion images were acquired using a pseudo-continuous ASL (pCASL) sequence with 2-dimensional (2D) gradient-echo echo-planar imaging (GE EPI) with a delay of 700 ms inserted between the end of the labeling pulse and image acquisition and the following parameters: repetition time (TR) = 3.5 s, echo time (TE) = 17 ms, labeling time = 1.5 s, delay time=1s, flip angle=90°, field of view (FOV) = and 220 × 220 mm2, matrix = 64 × 64, slice thickness = 6 mm, inter-slice gap = 2 mm.
42-1	7040-7049	Following	_
42-2	7050-7061	acquisition	_
42-3	7062-7064	of	_
42-4	7065-7068	the	_
42-5	7069-7079	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
42-6	7080-7085	scans	_
42-7	7086-7087	,	_
42-8	7088-7091	ASL	http://maven.renci.org/NeuroBridge/neurobridge#GasLevel
42-9	7092-7101	perfusion	_
42-10	7102-7108	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
42-11	7109-7113	were	_
42-12	7114-7122	acquired	_
42-13	7123-7128	using	_
42-14	7129-7130	a	_
42-15	7131-7148	pseudo-continuous	_
42-16	7149-7152	ASL	http://maven.renci.org/NeuroBridge/neurobridge#Reference
42-17	7153-7154	(	http://maven.renci.org/NeuroBridge/neurobridge#Reference
42-18	7155-7160	pCASL	http://maven.renci.org/NeuroBridge/neurobridge#Reference
42-19	7161-7162	)	http://maven.renci.org/NeuroBridge/neurobridge#Reference
42-20	7163-7171	sequence	http://maven.renci.org/NeuroBridge/neurobridge#Reference
42-21	7172-7176	with	_
42-22	7177-7190	2-dimensional	_
42-23	7191-7192	(	_
42-24	7193-7195	2D	_
42-25	7196-7197	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
42-26	7198-7211	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-27	7212-7223	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-28	7224-7231	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-29	7232-7233	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
42-30	7234-7236	GE	_
42-31	7237-7240	EPI	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
42-32	7241-7242	)	http://maven.renci.org/NeuroBridge/neurobridge#Episodic
42-33	7243-7247	with	_
42-34	7248-7249	a	_
42-35	7250-7255	delay	_
42-36	7256-7258	of	_
42-37	7259-7262	700	_
42-38	7263-7265	ms	_
42-39	7266-7274	inserted	_
42-40	7275-7282	between	_
42-41	7283-7286	the	_
42-42	7287-7290	end	_
42-43	7291-7293	of	_
42-44	7294-7297	the	_
42-45	7298-7306	labeling	_
42-46	7307-7312	pulse	_
42-47	7313-7316	and	_
42-48	7317-7322	image	_
42-49	7323-7334	acquisition	_
42-50	7335-7338	and	_
42-51	7339-7342	the	_
42-52	7343-7352	following	_
42-53	7353-7363	parameters	_
42-54	7364-7365	:	_
42-55	7366-7376	repetition	_
42-56	7377-7381	time	_
42-57	7382-7383	(	_
42-58	7384-7386	TR	_
42-59	7387-7388	)	_
42-60	7389-7390	=	_
42-61	7391-7394	3.5	_
42-62	7395-7396	s	_
42-63	7397-7398	,	_
42-64	7399-7403	echo	_
42-65	7404-7408	time	_
42-66	7409-7410	(	_
42-67	7411-7413	TE	_
42-68	7414-7415	)	_
42-69	7416-7417	=	_
42-70	7418-7420	17	_
42-71	7421-7423	ms	_
42-72	7424-7425	,	_
42-73	7426-7434	labeling	_
42-74	7435-7439	time	_
42-75	7440-7441	=	_
42-76	7442-7445	1.5	_
42-77	7446-7447	s	_
42-78	7448-7449	,	_
42-79	7450-7455	delay	_
42-80	7456-7463	time=1s	_
42-81	7464-7465	,	_
42-82	7466-7470	flip	_
42-83	7471-7480	angle=90°	_
42-84	7481-7482	,	_
42-85	7483-7488	field	_
42-86	7489-7491	of	_
42-87	7492-7496	view	_
42-88	7497-7498	(	_
42-89	7499-7502	FOV	_
42-90	7503-7504	)	_
42-91	7505-7506	=	_
42-92	7507-7510	and	_
42-93	7511-7514	220	_
42-94	7515-7516	×	_
42-95	7517-7520	220	_
42-96	7521-7524	mm2	_
42-97	7525-7526	,	_
42-98	7527-7533	matrix	_
42-99	7534-7535	=	_
42-100	7536-7538	64	_
42-101	7539-7540	×	_
42-102	7541-7543	64	_
42-103	7544-7545	,	_
42-104	7546-7551	slice	_
42-105	7552-7561	thickness	_
42-106	7562-7563	=	_
42-107	7564-7565	6	_
42-108	7566-7568	mm	_
42-109	7569-7570	,	_
42-110	7571-7582	inter-slice	_
42-111	7583-7586	gap	_
42-112	7587-7588	=	_
42-113	7589-7590	2	_
42-114	7591-7593	mm	_
42-115	7594-7595	.	_

Text=The ASL resting perfusion scan was 5 min in length, providing 45 acquisitions.
43-1	7596-7599	The	_
43-2	7600-7603	ASL	http://maven.renci.org/NeuroBridge/neurobridge#GasLevel
43-3	7604-7611	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-4	7612-7621	perfusion	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-5	7622-7626	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
43-6	7627-7630	was	_
43-7	7631-7632	5	_
43-8	7633-7636	min	_
43-9	7637-7639	in	_
43-10	7640-7646	length	_
43-11	7647-7648	,	_
43-12	7649-7658	providing	_
43-13	7659-7661	45	_
43-14	7662-7674	acquisitions	_
43-15	7675-7676	.	_

Text=2.4.
44-1	7677-7680	2.4	_
44-2	7681-7682	.	_

Text=Data analyses Imaging data analyses were performed using Statistical Parametric Mapping software (SPM8; Wellcome Department of Cognitive Neurology, London, UK) running on Matlab R2013a (Math Works, Natick, MA).
45-1	7683-7687	Data	_
45-2	7688-7696	analyses	_
45-3	7697-7704	Imaging	_
45-4	7705-7709	data	_
45-5	7710-7718	analyses	_
45-6	7719-7723	were	_
45-7	7724-7733	performed	_
45-8	7734-7739	using	_
45-9	7740-7751	Statistical	_
45-10	7752-7762	Parametric	_
45-11	7763-7770	Mapping	_
45-12	7771-7779	software	_
45-13	7780-7781	(	_
45-14	7782-7786	SPM8	_
45-15	7787-7788	;	_
45-16	7789-7797	Wellcome	_
45-17	7798-7808	Department	_
45-18	7809-7811	of	_
45-19	7812-7821	Cognitive	_
45-20	7822-7831	Neurology	_
45-21	7832-7833	,	_
45-22	7834-7840	London	_
45-23	7841-7842	,	_
45-24	7843-7845	UK	_
45-25	7846-7847	)	_
45-26	7848-7855	running	_
45-27	7856-7858	on	_
45-28	7859-7865	Matlab	_
45-29	7866-7872	R2013a	_
45-30	7873-7874	(	_
45-31	7875-7879	Math	_
45-32	7880-7885	Works	_
45-33	7886-7887	,	_
45-34	7888-7894	Natick	_
45-35	7895-7896	,	_
45-36	7897-7899	MA	_
45-37	7900-7901	)	_
45-38	7902-7903	.	_

Text=For each subject, functional images were realigned to correct for head motion and co-registered with each individual ’ s anatomical image.
46-1	7904-7907	For	_
46-2	7908-7912	each	_
46-3	7913-7920	subject	_
46-4	7921-7922	,	_
46-5	7923-7933	functional	_
46-6	7934-7940	images	_
46-7	7941-7945	were	_
46-8	7946-7955	realigned	_
46-9	7956-7958	to	_
46-10	7959-7966	correct	_
46-11	7967-7970	for	_
46-12	7971-7975	head	_
46-13	7976-7982	motion	_
46-14	7983-7986	and	_
46-15	7987-8000	co-registered	_
46-16	8001-8005	with	_
46-17	8006-8010	each	_
46-18	8011-8021	individual	_
46-19	8022-8023	’	_
46-20	8024-8025	s	_
46-21	8026-8036	anatomical	_
46-22	8037-8042	image	_
46-23	8043-8044	.	_

Text=Perfusion weighted image series were then generated by pairwise subtraction of the label and control images, followed by conversion to absolute CBF image series based on a single compartment CASL perfusion model.
47-1	8045-8054	Perfusion	_
47-2	8055-8063	weighted	_
47-3	8064-8069	image	_
47-4	8070-8076	series	_
47-5	8077-8081	were	_
47-6	8082-8086	then	_
47-7	8087-8096	generated	_
47-8	8097-8099	by	_
47-9	8100-8108	pairwise	_
47-10	8109-8120	subtraction	_
47-11	8121-8123	of	_
47-12	8124-8127	the	_
47-13	8128-8133	label	_
47-14	8134-8137	and	_
47-15	8138-8145	control	_
47-16	8146-8152	images	_
47-17	8153-8154	,	_
47-18	8155-8163	followed	_
47-19	8164-8166	by	_
47-20	8167-8177	conversion	_
47-21	8178-8180	to	_
47-22	8181-8189	absolute	_
47-23	8190-8193	CBF	_
47-24	8194-8199	image	_
47-25	8200-8206	series	_
47-26	8207-8212	based	_
47-27	8213-8215	on	_
47-28	8216-8217	a	_
47-29	8218-8224	single	_
47-30	8225-8236	compartment	_
47-31	8237-8241	CASL	_
47-32	8242-8251	perfusion	_
47-33	8252-8257	model	_
47-34	8258-8259	.	_

Text=For each subject, one mean resting CBF image was generated, normalized to the Montreal Neurological Institute (MNI) template, smoothed with a 3-D 9 mm Full Width Half Maximum (FWHM) isotropic Gaussian kernel, and then entered into the whole brain voxel-wise analysis using the general linear model (GLM).
48-1	8260-8263	For	_
48-2	8264-8268	each	_
48-3	8269-8276	subject	_
48-4	8277-8278	,	_
48-5	8279-8282	one	_
48-6	8283-8287	mean	_
48-7	8288-8295	resting	_
48-8	8296-8299	CBF	_
48-9	8300-8305	image	_
48-10	8306-8309	was	_
48-11	8310-8319	generated	_
48-12	8320-8321	,	_
48-13	8322-8332	normalized	_
48-14	8333-8335	to	_
48-15	8336-8339	the	_
48-16	8340-8348	Montreal	_
48-17	8349-8361	Neurological	_
48-18	8362-8371	Institute	_
48-19	8372-8373	(	_
48-20	8374-8377	MNI	_
48-21	8378-8379	)	_
48-22	8380-8388	template	_
48-23	8389-8390	,	_
48-24	8391-8399	smoothed	_
48-25	8400-8404	with	_
48-26	8405-8406	a	_
48-27	8407-8410	3-D	_
48-28	8411-8412	9	_
48-29	8413-8415	mm	_
48-30	8416-8420	Full	_
48-31	8421-8426	Width	_
48-32	8427-8431	Half	_
48-33	8432-8439	Maximum	_
48-34	8440-8441	(	_
48-35	8442-8446	FWHM	_
48-36	8447-8448	)	_
48-37	8449-8458	isotropic	_
48-38	8459-8467	Gaussian	_
48-39	8468-8474	kernel	_
48-40	8475-8476	,	_
48-41	8477-8480	and	_
48-42	8481-8485	then	_
48-43	8486-8493	entered	_
48-44	8494-8498	into	_
48-45	8499-8502	the	_
48-46	8503-8508	whole	_
48-47	8509-8514	brain	_
48-48	8515-8525	voxel-wise	_
48-49	8526-8534	analysis	_
48-50	8535-8540	using	_
48-51	8541-8544	the	_
48-52	8545-8552	general	_
48-53	8553-8559	linear	_
48-54	8560-8565	model	_
48-55	8566-8567	(	_
48-56	8568-8571	GLM	_
48-57	8572-8573	)	_
48-58	8574-8575	.	_

Text=Age and sex were included as covariates in all analyses.
49-1	8576-8579	Age	_
49-2	8580-8583	and	_
49-3	8584-8587	sex	_
49-4	8588-8592	were	_
49-5	8593-8601	included	_
49-6	8602-8604	as	_
49-7	8605-8615	covariates	_
49-8	8616-8618	in	_
49-9	8619-8622	all	_
49-10	8623-8631	analyses	_
49-11	8632-8633	.	_

Text=A paired t-test was conducted to compare rCBF between SMK and ABS conditions using a cluster forming height threshold of p <0.001.
50-1	8634-8635	A	_
50-2	8636-8642	paired	_
50-3	8643-8649	t-test	_
50-4	8650-8653	was	_
50-5	8654-8663	conducted	_
50-6	8664-8666	to	_
50-7	8667-8674	compare	_
50-8	8675-8679	rCBF	_
50-9	8680-8687	between	_
50-10	8688-8691	SMK	_
50-11	8692-8695	and	_
50-12	8696-8699	ABS	_
50-13	8700-8710	conditions	_
50-14	8711-8716	using	_
50-15	8717-8718	a	_
50-16	8719-8726	cluster	_
50-17	8727-8734	forming	_
50-18	8735-8741	height	_
50-19	8742-8751	threshold	_
50-20	8752-8754	of	_
50-21	8755-8756	p	_
50-22	8757-8758	<	_
50-23	8759-8764	0.001	_
50-24	8765-8766	.	_

Text=To control for Type I error, the most updated and accurate correction method for controlling for false positives provided by AFNI, 3dttest+ +, was used (AFNI_17.1.07), resulting in a 5% probability of a cluster surviving due to chance (α = 0.01, 943 contiguous voxels).
51-1	8767-8769	To	_
51-2	8770-8777	control	_
51-3	8778-8781	for	_
51-4	8782-8786	Type	_
51-5	8787-8788	I	_
51-6	8789-8794	error	_
51-7	8795-8796	,	_
51-8	8797-8800	the	_
51-9	8801-8805	most	_
51-10	8806-8813	updated	_
51-11	8814-8817	and	_
51-12	8818-8826	accurate	_
51-13	8827-8837	correction	_
51-14	8838-8844	method	_
51-15	8845-8848	for	_
51-16	8849-8860	controlling	_
51-17	8861-8864	for	_
51-18	8865-8870	false	_
51-19	8871-8880	positives	_
51-20	8881-8889	provided	_
51-21	8890-8892	by	_
51-22	8893-8897	AFNI	_
51-23	8898-8899	,	_
51-24	8900-8908	3dttest+	_
51-25	8909-8910	+	_
51-26	8911-8912	,	_
51-27	8913-8916	was	_
51-28	8917-8921	used	_
51-29	8922-8923	(	_
51-30	8924-8936	AFNI_17.1.07	_
51-31	8937-8938	)	_
51-32	8939-8940	,	_
51-33	8941-8950	resulting	_
51-34	8951-8953	in	_
51-35	8954-8955	a	_
51-36	8956-8957	5	_
51-37	8958-8959	%	_
51-38	8960-8971	probability	_
51-39	8972-8974	of	_
51-40	8975-8976	a	_
51-41	8977-8984	cluster	_
51-42	8985-8994	surviving	_
51-43	8995-8998	due	_
51-44	8999-9001	to	_
51-45	9002-9008	chance	_
51-46	9009-9010	(	_
51-47	9011-9012	α	_
51-48	9013-9014	=	_
51-49	9015-9019	0.01	_
51-50	9020-9021	,	_
51-51	9022-9025	943	_
51-52	9026-9036	contiguous	_
51-53	9037-9043	voxels	_
51-54	9044-9045	)	_
51-55	9046-9047	.	_

Text=All listed coordinates are in MNI space.
52-1	9048-9051	All	_
52-2	9052-9058	listed	_
52-3	9059-9070	coordinates	_
52-4	9071-9074	are	_
52-5	9075-9077	in	_
52-6	9078-9081	MNI	_
52-7	9082-9087	space	_
52-8	9088-9089	.	_

Text=To explore associations between brain and relevant smoking behavioral measures, simple regression analyses were conducted in SPM on the change in rCBF from SMK to ABS conditions, using the change in craving scores from SMK to ABS conditions (Item 3 of the CWQ) and FTND scores as covariates of interest.
53-1	9090-9092	To	_
53-2	9093-9100	explore	_
53-3	9101-9113	associations	_
53-4	9114-9121	between	_
53-5	9122-9127	brain	_
53-6	9128-9131	and	_
53-7	9132-9140	relevant	_
53-8	9141-9148	smoking	_
53-9	9149-9159	behavioral	_
53-10	9160-9168	measures	_
53-11	9169-9170	,	_
53-12	9171-9177	simple	_
53-13	9178-9188	regression	_
53-14	9189-9197	analyses	_
53-15	9198-9202	were	_
53-16	9203-9212	conducted	_
53-17	9213-9215	in	_
53-18	9216-9219	SPM	_
53-19	9220-9222	on	_
53-20	9223-9226	the	_
53-21	9227-9233	change	_
53-22	9234-9236	in	_
53-23	9237-9241	rCBF	_
53-24	9242-9246	from	_
53-25	9247-9250	SMK	_
53-26	9251-9253	to	_
53-27	9254-9257	ABS	_
53-28	9258-9268	conditions	_
53-29	9269-9270	,	_
53-30	9271-9276	using	_
53-31	9277-9280	the	_
53-32	9281-9287	change	_
53-33	9288-9290	in	_
53-34	9291-9298	craving	_
53-35	9299-9305	scores	_
53-36	9306-9310	from	_
53-37	9311-9314	SMK	_
53-38	9315-9317	to	_
53-39	9318-9321	ABS	_
53-40	9322-9332	conditions	_
53-41	9333-9334	(	_
53-42	9335-9339	Item	_
53-43	9340-9341	3	_
53-44	9342-9344	of	_
53-45	9345-9348	the	_
53-46	9349-9352	CWQ	_
53-47	9353-9354	)	_
53-48	9355-9358	and	_
53-49	9359-9363	FTND	_
53-50	9364-9370	scores	_
53-51	9371-9373	as	_
53-52	9374-9384	covariates	_
53-53	9385-9387	of	_
53-54	9388-9396	interest	_
53-55	9397-9398	.	_

Text=The same corrections used for rCBF contrasts were applied prior to extracting significant rCBF values from each of the functionally-identified clusters within each subject using MarsBaR and statistical analyses were conducted in SPSS version 22.
54-1	9399-9402	The	_
54-2	9403-9407	same	_
54-3	9408-9419	corrections	_
54-4	9420-9424	used	_
54-5	9425-9428	for	_
54-6	9429-9433	rCBF	_
54-7	9434-9443	contrasts	_
54-8	9444-9448	were	_
54-9	9449-9456	applied	_
54-10	9457-9462	prior	_
54-11	9463-9465	to	_
54-12	9466-9476	extracting	_
54-13	9477-9488	significant	_
54-14	9489-9493	rCBF	_
54-15	9494-9500	values	_
54-16	9501-9505	from	_
54-17	9506-9510	each	_
54-18	9511-9513	of	_
54-19	9514-9517	the	_
54-20	9518-9541	functionally-identified	_
54-21	9542-9550	clusters	_
54-22	9551-9557	within	_
54-23	9558-9562	each	_
54-24	9563-9570	subject	_
54-25	9571-9576	using	_
54-26	9577-9584	MarsBaR	_
54-27	9585-9588	and	_
54-28	9589-9600	statistical	_
54-29	9601-9609	analyses	_
54-30	9610-9614	were	_
54-31	9615-9624	conducted	_
54-32	9625-9627	in	_
54-33	9628-9632	SPSS	_
54-34	9633-9640	version	_
54-35	9641-9643	22	_
54-36	9644-9645	.	_

Text=Similarly, an exploratory post hoc analysis was conducted on the change in rCBF from SMK to ABS conditions using the focus/attention item of the Shiffman-Jarvik Withdrawal Scale as a covariate of interest.
55-1	9646-9655	Similarly	_
55-2	9656-9657	,	_
55-3	9658-9660	an	_
55-4	9661-9672	exploratory	_
55-5	9673-9677	post	_
55-6	9678-9681	hoc	_
55-7	9682-9690	analysis	_
55-8	9691-9694	was	_
55-9	9695-9704	conducted	_
55-10	9705-9707	on	_
55-11	9708-9711	the	_
55-12	9712-9718	change	_
55-13	9719-9721	in	_
55-14	9722-9726	rCBF	_
55-15	9727-9731	from	_
55-16	9732-9735	SMK	_
55-17	9736-9738	to	_
55-18	9739-9742	ABS	_
55-19	9743-9753	conditions	_
55-20	9754-9759	using	_
55-21	9760-9763	the	_
55-22	9764-9779	focus/attention	_
55-23	9780-9784	item	_
55-24	9785-9787	of	_
55-25	9788-9791	the	_
55-26	9792-9807	Shiffman-Jarvik	_
55-27	9808-9818	Withdrawal	_
55-28	9819-9824	Scale	_
55-29	9825-9827	as	_
55-30	9828-9829	a	_
55-31	9830-9839	covariate	_
55-32	9840-9842	of	_
55-33	9843-9851	interest	_
55-34	9852-9853	.	_

Text=Continuous demographic variables and FTND scores were summarized by calculating means and standard error measurements (X ± SEMs).
56-1	9854-9864	Continuous	_
56-2	9865-9876	demographic	_
56-3	9877-9886	variables	_
56-4	9887-9890	and	_
56-5	9891-9895	FTND	_
56-6	9896-9902	scores	_
56-7	9903-9907	were	_
56-8	9908-9918	summarized	_
56-9	9919-9921	by	_
56-10	9922-9933	calculating	_
56-11	9934-9939	means	_
56-12	9940-9943	and	_
56-13	9944-9952	standard	_
56-14	9953-9958	error	_
56-15	9959-9971	measurements	_
56-16	9972-9973	(	_
56-17	9974-9975	X	_
56-18	9976-9977	±	_
56-19	9978-9982	SEMs	_
56-20	9983-9984	)	_
56-21	9985-9986	.	_

Text=A paired t-test was used to assess differences across conditions in CWQ items and the focus/attention item of the Shiffman-Jarvik Scale (post hoc).
57-1	9987-9988	A	_
57-2	9989-9995	paired	_
57-3	9996-10002	t-test	_
57-4	10003-10006	was	_
57-5	10007-10011	used	_
57-6	10012-10014	to	_
57-7	10015-10021	assess	_
57-8	10022-10033	differences	_
57-9	10034-10040	across	_
57-10	10041-10051	conditions	_
57-11	10052-10054	in	_
57-12	10055-10058	CWQ	_
57-13	10059-10064	items	_
57-14	10065-10068	and	_
57-15	10069-10072	the	_
57-16	10073-10088	focus/attention	_
57-17	10089-10093	item	_
57-18	10094-10096	of	_
57-19	10097-10100	the	_
57-20	10101-10116	Shiffman-Jarvik	_
57-21	10117-10122	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
57-22	10123-10124	(	_
57-23	10125-10129	post	_
57-24	10130-10133	hoc	_
57-25	10134-10135	)	_
57-26	10136-10137	.	_

Text=Statistical analyses were conducted in SPSS version 22.0.
58-1	10138-10149	Statistical	_
58-2	10150-10158	analyses	_
58-3	10159-10163	were	_
58-4	10164-10173	conducted	_
58-5	10174-10176	in	_
58-6	10177-10181	SPSS	_
58-7	10182-10189	version	_
58-8	10190-10194	22.0	_
58-9	10195-10196	.	_

